Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stentsopen access
- Authors
- Kim, Yong Hoon; Her, Ae-Young; Jeong, Myung Ho; Kim, Byeong-Keuk; Hong, Sung-Jin; Park, Sang-Ho; Kim, Seunghwan; Ahn, Chul-Min; Kim, Jung-Sun; Ko, Young-Guk; Choi, Donghoon; Hong, Myeong-Ki; Jang, Yangsoo
- Issue Date
- Aug-2023
- Publisher
- VIA MEDICA
- Keywords
- angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; myocardial infarction; prediabetes; outcomes
- Citation
- CARDIOLOGY JOURNAL, v.30, no.4, pp 614 - 626
- Pages
- 13
- Journal Title
- CARDIOLOGY JOURNAL
- Volume
- 30
- Number
- 4
- Start Page
- 614
- End Page
- 626
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25577
- DOI
- 10.5603/CJ.a2021.0116
- ISSN
- 1897-5593
1898-018X
- Abstract
- Background: Because limited data are available, the present study investigated 2-year major clinical outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful implantation of newer-generation drug-eluting stents (DESs).Methods: Overall, 2932 patients with AMI and prediabetes were classified into two groups - the ACEIs group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the occurrence of patient-orientedcomposite outcome (POCO), defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat revascularization. The secondary endpoint was definite or probable stent thrombosis (ST).Results: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% confidence interval [CI]: 0.740-1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 0.803-2.419; p = 0.238), Re-MI (aHR: 1.210; 95% CI: 0.626-2.340; p = 0.570), any repeat revascularization (aHR: 1.150; 95% CI: 0.713-1.855; p = 0.568), and ST (aHR: 1.736; 95% CI: 0.445-6.766; p = 0.427) were similar between the groups. These results were confirmed after propensity score-adjusted analysis.Conclusions: In this study, patients with AMI and prediabetes who received ACEIs or ARBs showed comparable clinical outcomes during the 2-year follow-up period. (Cardiol J 2023; 30, 4: 614-626)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25577)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.